Sprint Bioscience sells the TREX1 program to Gilead
The agreement includes an upfront payment of USD 14 million, as well as potential clinical, regulatory, and commercial milestone payments totaling up to USD 400 million.
November 24, 2025
“We are pleased to enter into this agreement with Gilead, whom we value highly as a business partner. We appreciate their forward-looking approach and strong commitment to cutting-edge pharmaceutical development. TREX1 has demonstrated significant potential in the pre-clinical phase, and our decision to sell the program, rather than license it, reflects a strategic shift toward more flexible, value-driven exit opportunities,” says Johan Emilsson, CEO of Sprint Bioscience.
Sprint Bioscience licenses program to Day One Biopharmaceuticals
Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals Inc. “This agreement is yet another confirmation that the work we do within the company is of the highest international class. The VADA (VRK1) program has generated great interest in the industry globally and we have chosen Day […]
Published: November 24, 2025
